The present invention relates to adjuvants of the glycolipid type and their uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides uses of compounds useful as adjuvants for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumours and allergies. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants.